UBS Global Life Sciences Conference

Transcription

1 September 21, 2010 UBS Global Life Sciences Conference Tecan Group AG Thomas Bachmann, CEO

2 September 21, 2010 / p2 / UBS Global Life Sciences Conference Introducing Tecan Provider of instruments and workflow-solutions to the world s pharma, biotech, diagnostic and forensic laboratories and companies Our solutions accelerate, automate and enhance the processes in stateof-the-art life sciences laboratories Global leader in laboratory automation for 30 years Leading provider of OEM instruments and components HQ in Switzerland, 3 manufacturing and R&D sites; >1,100 employees; maintaining a sales and service network in 52 countries Listed at the SIX Swiss Exchange (TECN; TECN SW)

3 September 21, 2010 / p3 / UBS Global Life Sciences Conference Tecan s Markets, Customers, Applications Life Science Research Forensics Diagnostics Total size: 37bn USD Lab autom.: 2.5bn USD LT growth: 3% - 5% Total size: 1.3bn USD Automation: 470m USD LT growth: 15% Total size: 38bn USD Automation: 6bn USD LT growth: 5% - 7% Customers Pharmaceutical Companies Biotech Companies Academia CROs Government Institutions Research - Genomics - Proteomics - Cell-based Drug Discovery Production of proteins and cells Law Enforcement Agencies Government Laboratories Blood Banks Reference Laboratories Hospitals Diagnostics Companies (OEM) Applications Human Identification with DNA samples found at crime scenes, disaster sites etc. Proof of relationships Screening of populations or particular groups Blood typing Testing against diseases Pre- & post natal screening Personalized medicine and companion diagnostics

4 September 21, 2010 / p4 / UBS Global Life Sciences Conference New Group Organization Components & Detection Liquid Handling & Robotics sold/discontinued Sample Management Old product segmentation New customer segmentation Life Sciences Business Focused on all end-customer activities Partnering Business Focused on all OEM activities Development & Supply Operations Science & Technology

5 September 21, 2010 / p5 / UBS Global Life Sciences Conference Applications & Integrated Workflow Solutions Software Service Consumables Life Sciences Business User Interfaces Modules Instruments Quality & Regulatory Reagents 3rd Party Devices

6 September 21, 2010 / p6 / UBS Global Life Sciences Conference Various Co-Operation Models and Many Applications Life Sciences Business Numerous partnerships with global and local reagent and assay providers Tecan provides a number of innovative, off-the-shelf solutions that are specifically tailored for applications in the life sciences and diagnostics fields Tecan provides numerous sample preparation front-end solutions for widely used analyzers Increasing regulatory requirements demand for validated solutions Standardized workflow solutions gain in importance in all markets

7 September 21, 2010 / p7 / UBS Global Life Sciences Conference OEM Business Opportunity Partnering Business Today majority of OEM market is captive, i.e. instruments developed by IVD & LSR companies Trend towards outsourcing Focus on faster time to market, cost and existing service network OEM sales Components Instruments, Services & Consumables End-user Market ~$ 1.2bn* today ~$ 1.5bn* in 5 years OEM Market ~$ 6bn* ~10%* today OEM as a % of total sales OEM Business 27.7% 30.8% End-user Business ~$ 8bn* ~20%* in 5 years captive open *Tecan estimates 44.2% CHF (mio) H Total sales for all periods are from continuing operations only H1 2010

8 September 21, 2010 / p8 / UBS Global Life Sciences Conference Tecan s Broad OEM Offering Integrated Solutions Concepts developed by Tecan and showcased to potential partners Integrating instrument, plastic consumables and enabling reagents Partnering Business Customer Service & Spare Parts Dedicated Solutions Platform-based Solutions OEM Components Plastic Consumables

9 September 21, 2010 / p9 / UBS Global Life Sciences Conference Strategic Growth Driver: Services & Consumables Services & Consumables sales S&C as a % of total sales Life Sciences Business CHF (mio) Services Consumables Services & Consumables Instruments 29% 31% 32% H H Total sales for all periods are from continuing operations only Partnering Business Examples for sales per year: Diagnostics: CHF 15K (e.g. EVOlyzer, M2000) Forensics: CHF 20K (e.g. HID EVOlution) Life Science Research: CHF 50K (MCA 384 for high-throughput screening) Development of application-specific, patentable consumables underway Individual process or analytical steps taking place directly within consumable itself

10 September 21, 2010 / p10 / UBS Global Life Sciences Conference Strategic Growth Driver: Global Business Focus Life Sciences Business Partnering Business Major investments in public healthcare and life science research in emerging markets Recent global market development for Tecan end-user business: Asia Pacific HQ in Shanghai opened in October 2008; continued investments in infrastructure and market organization Project Ginseng in concept phase: defining growth case with new emerging markets products; building cost case for existing products to lower COGS Tecan implant with distributor to regain momentum in Australasia; potential to expand model to other markets Further growth opportunities in emerging markets through OEM partners Americas Europe, Near & Middle East, Africa Greater Asia

11 September 21, 2010 / p11 / UBS Global Life Sciences Conference H Strong Business Performance Significant sales growth in H1 2010: +9.1% in CHF and +12.2% in LC EBIT increased by 11.0% with EBIT margin of 13.0% (H1 2009: 12.8%) Global OEM business grew by 52.4%; now contributing 44% to total sales Strong performance in Services and Consumables (Consumables only: +17.5%); 32% of total sales Order entry increased by 7.4% in CHF and 10.7% in LC Strong cash flow from operating activities (11.7% of sales) Results from continuing operations only

12 September 21, 2010 / p12 / UBS Global Life Sciences Conference 2010 Outlook for Continuing Operations Sales guidance FY 2010 Sales growth above market average expected Aiming for growth between 6-8% in local currency terms EBIT Margin guidance FY % (including additional investments of up to CHF 3 million) Corresponding to % in 2009 constant currencies

13 Safe Harbor Statement All statements in this presentation not referring to historical facts are predictions of the future and constitute no guarantee whatsoever of future performances. They are subject to risks and uncertainties including, but not limited to, future global economic conditions, exchange rates, legal regulations, market conditions, activities of competitors and other factors outside the Company s control. Tecan Group AG is making all efforts to include accurate and up-to-date information into this presentation. Yet, it cannot be ruled out that omissions or errors might have occurred. Therefore, Tecan Group AG cannot make any representations or warranties, expressed or implied, as to the accuracy or completeness of the information provided in this presentation. Changes in this presentation can be made any time without notice. All mentioned trademarks are protected by law. Tecan Group AG, Tecan Trading AG, Switzerland, all rights reserved.